Site Search
The investment will go toward finishing a Phase 2a clinical trial for an anti-infective to treat chronic infections in people with CF.
Bill will jump-start rebuilding of the antibiotics pipeline that is vital to stave off a looming pandemic.
Today, the Cystic Fibrosis Foundation announced plans to improve lung transplantation for people with CF at an Organ Summit, hosted by the White House. The event focused on new and innovative ways to improve outcomes for individuals waiting for organ transplants and to improve support for living donors.
Piper Beatty, a two-time double-lung transplant recipient, testifies at an FDA meeting on organ transplantation.
The studies aim to improve our understanding of a common cause of lung transplant failures, a condition known as chronic lung allograft dysfunction (CLAD).
The Cystic Fibrosis Foundation has awarded up to $5.6 million to Microbion Corporation to develop a novel, inhaled antibiotic to treat drug-resistant bacterial infections in people with cystic fibrosis.
The Cystic Fibrosis Foundation has been carefully following the story of a 10-year-old girl with cystic fibrosis who has severe lung disease and has been on a pediatric lung transplant list for 18 months. Her family has organized an online petition and filed a lawsuit to help her receive an adult donor lung.
The U.S. Food and Drug Administration (FDA) has approved TOBI® Podhaler™ (tobramycin inhalation powder), a dry powder formulation of the antibiotic TOBI, to treat lung infections caused by the bacteria Pseudomonas aeruginosa (P. aeruginosa).